Pharma BD Deal Intelligence
Endo's $370M cash-plus-milestones acquisition of Indevus never paid off: marquee pipeline asset Aveed was serially rejected by the FDA and didn't reach market until 2014, five years after close, while Endo booked tens of millions in impairments and the acquirer itself later collapsed into opioid-liability bankruptcy.
A sub-scale diversification bolt-on whose marquee pipeline asset was serially rejected by the FDA and never became more than a niche product line, inside a company that itself later collapsed into opioid-liability bankruptcy.
Full analysis, sources & comparables →Endo's $370M cash bid plus up to $267M milestones for Indevus diversifies the buyer well beyond pain into urology and endocrinology specialty franchises.
On closing, Indevus becomes a wholly owned Endo subsidiary, with Sanctura/Sanctura XR, Vantas, Supprelin LA, Delatestryl, and a near-term Valstar relaunch…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Announced Jan 5, 2009; closed Feb 2009. $370M cash + up to $267M milestones. Urology/endo/oncology (Vantas, Valstar). Source: SEC 8-K, Fierce Biotech.
A sub-scale diversification bolt-on whose marquee pipeline asset was serially rejected by the FDA and never became more than a niche product line, inside a company that itself later collapsed into opioid-liability bankruptcy.
Assessment window: 15yr post-close.
Overactive bladder (OAB) is a syndrome of urinary urgency, frequency, and urge incontinence affecting roughly 30 million US adults; advanced prostate cancer, central precocious puberty, and male hypogonadism are smaller specialty-urology/endocrinology niches. These categories are call-point-concentrated around urologists and pediatric endocrinologists, making them attractive bolt-ons for specialty pharmas seeking sales-force leverage.
At the time of the 2009 Endo-Indevus deal, the OAB anticholinergic market was led by Pfizer's Detrol/Detrol LA (tolterodine), Astellas/GSK's Vesicare (solifenacin), J&J's Ditropan XL (oxybutynin), and Novartis' Enablex (darifenacin), with newer beta-3 agonists (Astellas' Myrbetriq) still in development. Indevus' Sanctura and Sanctura XR (trospium chloride) competed as a non-tertiary-amine option positioned on lower CNS penetration. The acquired portfolio also included Vantas (histrelin implant for advanced prostate cancer, competing with AbbVie's Lupron Depot and Sanofi's Eligard), Supprelin LA (histrelin for central precocious puberty), Delatestryl (testosterone enanthate for male hypogonadism), and a relaunch-ready Valstar (valrubicin) for BCG-refractory bladder cancer (Endo 8-K, Jan 5 2009). Endo paid ~$370M cash up front plus up to ~$267M in milestones tied largely to NEBIDO (testosterone undecanoate) and pipeline assets, leveraging an existing pain-and-specialty sales force into urology/endo and diversifying away from Lidoderm and Opana ahead of expected pain-franchise pressure (FierceBiotech, BioSpace, Jan-Mar 2009).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo Pharmaceuticals Inc. / Indevus Pharmaceuticals, Inc. (this deal) | 2009 | $370M | 33 |
| Endo Pharmaceuticals Inc. / Algos Pharmaceutical Corporation | 2000 | $250M | 34 |
| Endo Pharmaceuticals Inc. / SkyePharma plc | 2003 | $120M | 17 |
| Endo Pharmaceuticals Inc. / HealthTronics, Inc. | 2010 | $223M | 17 |
| Endo Pharmaceuticals Inc. / Qualitest Pharmaceuticals | 2010 | $1.2B | 17 |
| Endo Pharmaceuticals Inc. / American Medical Systems Holdings, Inc. | 2011 | $2.9B | 13 |
| Endo Pharmaceuticals Inc. / Penwest Pharmaceuticals Co. | 2010 | $144M | 13 |